IAS 2005: Index of Coverage

Now Live: Breaking Research From AIDS 2008: Podcasts, Interviews, Videos & More >>

Key Links:

By Topic:

Search:

Complications of HIV/HAART

Adverse Event Risk on Abacavir + Lamivudine Is Not Higher for Patients Coinfected With Hepatitis B and/or Hepatitis C (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Fosamprenavir + Ritonavir Appears Safe Through 120 Weeks in HIV/HBV and HIV/HCV-Coinfected Patients (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Incidence of Zidovudine-Associated Anemia May Be Lower Than Initially Thought -- Particularly With Fixed-Dose Combinations (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Low Incidence of Abacavir Hypersensitivity Reaction in Treatment-Naive and -Experienced Patients (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Renal Dysfunction in HIV Not Uncommon, but HAART Generally Not a Cause (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
The Price of Progress: A Review of Immune Reconstitution Syndrome (July 26, 2005)
To download PowerPoint, click here.
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment

Developing World

Heroin Use Contributing to HIV Spread in Eurasia (July 26, 2005)
HIV prevalence is reportedly rising in Belarus, Moldavia, Tajikistan, Ukraine and other countries along the drug trafficking route from Afghanistan to Eastern Europe.
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation

Drug Resistance

No K65R Mutations in Patients Failing Tenofovir + Emtricitabine (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Conference Presentation Provides Overview of Some Drug Resistance Assays (July 25, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
The Link Between Unsafe Sex, Poor HAART Adherence, Resistance and Drug Resistant HIV Transmission (July 25, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment

HIV Transmission

Male Circumcision Might Reduce Risk of Female-to-Male HIV Transmission by About 65%, Study Finds (July 27, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation

New HIV Treatments

D-D4FC (RVT, Reverset) Is Active Against NRTI-Resistant Virus in Phase 2B Trial (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
GW695634 Demonstrates Potent Activity in 7-Day Monotherapy Study in an NNRTI Treatment-Experienced Population (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
TMC114 Significantly Outperforms Control Protease Inhibitors in Triple-Class-Experienced Patients, Even in Absence of Enfuvirtide (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
873140, a CCR5 Antagonist, Displays Activity Against R5-Tropic Virus in Naive and Experienced Patients (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
The CCR5 Antagonist UK-427,857 (Maraviroc) Shows Strong Activity in Phase 1/2a Monotherapy Studies (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Treatment With Growth Hormone Leads to Improvement in CD4 T-Cell Counts in HIV-Infected Adults on HAART (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Vicriviroc (SCH 417690, SCH-D), a CCR5 Antagonist, Generally Well Tolerated and Effective in 14-Day Monotherapy Study (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment

Pathogenesis

HIV Eradication Still a Dream Because of the Persistence of a Latent Reservoir (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment

Rescue Therapy

Lamivudine Monotherapy Better Than Treatment Interruption in Rescue Patients With M184V (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Tipranavir Heralds New Era for Treatment-Experienced Patients, Recent Studies Attest (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment

Treatment Strategies

Coming Soon: New Lopinavir/Ritonavir (Kaletra) Formulation Allowing for 2-Tablet, Twice-Daily Dosing (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Full Virologic Suppression Can Be Maintained With Lopinavir/Ritonavir Alone; Single-Agent Therapies Worth Further Investigation (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Head-to-Head Comparison of Three Backbone Regimens With Efavirenz (July 27, 2005)
Although this study finds no clear winner, the abacavir + ddI arm appears to fall a bit short.
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
In Head-to-Head International Study, Tenofovir + Emtricitabine Bests Zidovudine/Lamivudine in Tolerability and Convenience (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Nucleoside-Sparing Regimens: Promising, but Still Experimental (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Quad Nucleoside/tide Regimen of Trizivir + Tenofovir Effective, Well Tolerated as Second-Line Therapy (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Therapeutic Drug Monitoring Study Finds Adequate Drug Levels for Once-Daily Nevirapine (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.